KIR2DL1
Killer cell immunoglobulin-like receptor 2DL1
As of the edition of 20 October 2026, KIR2DL1 (killer cell immunoglobulin-like receptor 2DL1, UniProt P43626) has 2 drugs tested at it and 3 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P43626
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 4
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Lungs and airways; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive
- Registered trials of its drugs
- 17
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lirilumab | Stopped | Phase 2 | none listed |
| IPH-2101 | Went quiet | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Engaged | 2 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Incyte | Route A |
The other 2 companies at KIR2DL1
In the product3 companies in all; 2 are not named here, and no score is.
See the 3 companies at KIR2DL1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.